Dahan, Rony <br/><br/>
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.  [electronic resource] 

 -  Cancer cell  06 2016 
 - 820-831 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1878-3686 
<br/><br/><label>Standard No.: </label>10.1016/j.ccell.2016.05.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>CD40 Antigens--agonists<br/>Cell Line, Tumor<br/>Humans<br/>Immunotherapy<br/>Mice<br/>Neoplasms--drug therapy<br/>Receptors, IgG--immunology<br/>Xenograft Model Antitumor Assays